Samsung Bioepis and EpisNexLab to Jointly Develop Obesity Treatment with G2G Bio (Comprehensive)

Aiming to Develop Long-Acting Therapeutics
20 Billion Won Investment in G2G Bio Convertible Bonds

On March 16, Samsung Bioepis and EpisNexLab announced that they have signed a joint research and license agreement with G2G Bio for the development of long-acting obesity treatments.

Kim Kyung-Ah, President of Samsung Bioepis (center), Sungwon Hong, Vice President and CEO of Episnex Lab (left), and Heeyong Ji, CEO of G2G Bio (right) are posing for a commemorative photo after signing a contract for joint development of new bio-drugs and technology platforms. Samsung Bioepis

This is a tripartite agreement in which Samsung Bioepis, a biopharmaceutical developer, and EpisNexLab, a biotechnology platform developer, will use G2G Bio's microsphere-based drug delivery technology to develop long-acting obesity treatments and secure platform technology.

Under the agreement, Samsung Bioepis will acquire development and commercialization rights to G2G Bio's pipeline and will proceed with product development. EpisNexLab will conduct joint research with G2G Bio to establish a long-acting drug delivery technology platform.

Samsung Bioepis has signed a license agreement with G2G Bio that grants it exclusive development rights for two candidates, including a long-acting semaglutide-based obesity treatment, and will pay an upfront payment and milestone payments. EpisNexLab has entered into a joint research and development agreement to build a long-acting drug delivery technology platform.

The specific contract amount and terms were not disclosed. Samsung Bioepis and G2G Bio have also agreed on a condition granting preferential negotiation rights for the additional development of three more candidates, including new drug candidates, in the future.

On the same day, Samsung Epis Holdings signed a contract to invest in 20 billion won worth of convertible bonds (CB) issued by G2G Bio. Through this, the two companies have also established a financial investment-based business collaboration.

Kim Kyung-Ah, President of Samsung Epis Holdings, said, "This agreement will serve as an opportunity for our company to further grow as a comprehensive biopharmaceutical company through the development of new drugs in various fields to address unmet medical needs. It is a representative example of an open innovation strategy that maximizes the business synergy of each company under a holding company structure."

Heeyong Ji, CEO of G2G Bio, emphasized, "This agreement is significant in that it secures the production rights to supply products to the global market in connection with our planned second GMP facility. As our partners will bear the global development costs for two candidates, including the obesity treatment, this will serve as an opportunity to prove not only our technological capabilities but also our business value at the same time."

This content was produced with the assistance of AI translation services.